Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron(R) Through Phase 2b Development
(NASDAQ:DWTX),(HKSE:0775),(HKSE:0775.HK), Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced that it has entered into […]